Advertisement


Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Advertisement